Literature DB >> 24018190

Setting expectations in molecular optimizations: Strengths and limitations of commonly used composite parameters.

Michael D Shultz1.   

Abstract

Over the past 15years there have been extensive efforts to understand and reduce the high attrition rates of drug candidates with an increased focus on physicochemical properties. The fruits of this labor have been the generation of numerous efficiency indices, metric-based rules and visualization tools to help guide medicinal chemists in the design of new compounds with more favorable properties. This deluge of information may have had the unintended consequence of further obfuscating molecular optimizations by the inability of these scoring functions, rules and guides to reach a consensus on when a particular transformation is identified as beneficial. In this manuscript, several composite parameters, or efficiency indices, are examined utilizing theoretical and experimental matched molecular pair analyses in order to understand the basis for how each will perform under varying scenarios of molecular optimizations. In contrast to empirically derived composite parameters based on heavy atom count, lipophilic efficiency (LipE) sets consistent expectations regardless of molecular weight or relative potency and can be used to generate consistent expectations for any matched molecular pair.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Keywords:  Composite parameters; Efficiency metrics; Ligand efficiency; Lipophilic efficiency

Mesh:

Substances:

Year:  2013        PMID: 24018190     DOI: 10.1016/j.bmcl.2013.08.029

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  41 in total

1.  Thermodynamic Proxies to Compensate for Biases in Drug Discovery Methods.

Authors:  Sean Ekins; Nadia K Litterman; Christopher A Lipinski; Barry A Bunin
Journal:  Pharm Res       Date:  2015-08-27       Impact factor: 4.200

2.  Structure-Based Design and Synthesis of an Isozyme-Selective MTHFD2 Inhibitor with a Tricyclic Coumarin Scaffold.

Authors:  Junya Kawai; Masahiro Ota; Hitoshi Ohki; Tadashi Toki; Makoto Suzuki; Takashi Shimada; Satoshi Matsui; Hidekazu Inoue; Chika Sugihara; Norikazu Matsuhashi; Yumi Matsui; Sachiko Takaishi; Kiyoshi Nakayama
Journal:  ACS Med Chem Lett       Date:  2019-05-24       Impact factor: 4.345

3.  Structure-Based Discovery of New Antagonist and Biased Agonist Chemotypes for the Kappa Opioid Receptor.

Authors:  Zhong Zheng; Xi-Ping Huang; Thomas J Mangano; Rodger Zou; Xin Chen; Saheem A Zaidi; Bryan L Roth; Raymond C Stevens; Vsevolod Katritch
Journal:  J Med Chem       Date:  2017-04-03       Impact factor: 7.446

4.  Validity of ligand efficiency metrics.

Authors:  Christopher W Murray; Daniel A Erlanson; Andrew L Hopkins; György M Keserü; Paul D Leeson; David C Rees; Charles H Reynolds; Nicola J Richmond
Journal:  ACS Med Chem Lett       Date:  2014-05-09       Impact factor: 4.345

Review 5.  The role of ligand efficiency metrics in drug discovery.

Authors:  Andrew L Hopkins; György M Keserü; Paul D Leeson; David C Rees; Charles H Reynolds
Journal:  Nat Rev Drug Discov       Date:  2014-02       Impact factor: 84.694

6.  Improving the plausibility of success with inefficient metrics.

Authors:  Michael D Shultz
Journal:  ACS Med Chem Lett       Date:  2013-11-21       Impact factor: 4.345

7.  Ligand efficiency metrics considered harmful.

Authors:  Peter W Kenny; Andrei Leitão; Carlos A Montanari
Journal:  J Comput Aided Mol Des       Date:  2014-06-05       Impact factor: 3.686

8.  Ligand-based virtual screening identifies a family of selective cannabinoid receptor 2 agonists.

Authors:  Matteo Gianella-Borradori; Ivy Christou; Carole J R Bataille; Rebecca L Cross; Graham M Wynne; David R Greaves; Angela J Russell
Journal:  Bioorg Med Chem       Date:  2014-11-08       Impact factor: 3.641

9.  Translocator protein ligands based on N-methyl-(quinolin-4-yl)oxypropanamides with properties suitable for PET radioligand development.

Authors:  Chad Brouwer; Kimberly J Jenko; Sami S Zoghbi; Cheryl L Morse; Robert B Innis; Victor W Pike
Journal:  Eur J Med Chem       Date:  2016-08-25       Impact factor: 6.514

10.  Development of thieno- and benzopyrimidinone inhibitors of the Hedgehog signaling pathway reveals PDE4-dependent and PDE4-independent mechanisms of action.

Authors:  Jonathan E Hempel; Adrian G Cadar; Charles C Hong
Journal:  Bioorg Med Chem Lett       Date:  2016-03-07       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.